Non Hormonal Contraceptives Market

Non Hormonal Contraceptives Market by Target Indication, Type of Molecule, Purpose of Therapy, Mechanism of Action, Route of Administration and Key Geographies: Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    104

  • Pages
    225

  • View Count
    11805

Non Hormonal Contraceptives Market Overview

The non hormonal contraceptives market is estimated to be worth $1.8 billion in 2021 and is expected to grow at CAGR of 22% during the forecast period. According to the World Health Organization (WHO), sexual and reproductive health-related conditions represent around one third of all clinical conditions prevalent among women between the ages of 15 and 44 years. The human female reproductive system is complex and governed primarily by two hormones, estrogen and progesterone. Any imbalance in the levels of these hormones materializes in the form of a disease, and / or mood related disorders; in fact, women are more prone to experiencing various forms of anxiety, depression and certain physical symptoms that cannot yet be explained medically, as compared to men. Since hormones are responsible for almost all of the concerns associated with reproductive health, a number of hormone regulating interventions have been developed, and are available, for the treatment / prevention of the clinical conditions that are unique to women. This form of therapy has been proven to be both viable and effective, and have been in use since the 1960s. Such therapies gained better traction as mainstream healthcare solutions after clinical trials were conducted, proving their efficacy, in the late 1990s. Despite the vast success of using hormones as therapeutics, later studies reflected a positive correlation between the use of such interventions and several unwanted side effects, including the risk of developing hormone dependent cancers.

In recent years, the development and introduction of non hormonal contraceptives has revolutionized women’s healthcare. Brisdelle® was the first of such non hormonal contraceptives, approved in 2013 for the management of hot flashes in menopausal women. Till date, 21 non hormonal contraceptives (recent examples include Oriahnn™, Phexxi™ and Esmya®) have been approved. Further, several such non hormonal birth control drug candidates are under evaluation across different stages of product development. The inherent advantages of non hormonal birth control therapies, such as better safety profile, ability to maintain hormonal balance and relatively short treatment courses, over their hormonal counterparts have been demonstrated both in clinical trials and post product approval studies. As a result, such non hormonal contraceptives are currently preferred over hormone-based therapies, and the non hormonal birth control therapy pipeline is expected to continue to steadily expand over the coming years.It is worth highlighting that significant partnership activity has been observed in this market, with several stakeholders entering into strategic collaborations to support the ongoing product development and commercialization initiatives of such products. In the foreseen future, promising results from the ongoing clinical research initiatives are likely to bring in more investments to support product development activity in this upcoming market segment. Therefore, we are led to anticipate significant market growth in this domain during the forecast period.

Non-Hormonal-Contraceptives-Market-Context-Roots-thumb Non-Hormonal-Contraceptives-Market-Development-Pipeline-Roots-thumb Non-Hormonal-Contraceptives-Market-Phase-of-Development-Roots-thumb

Recent Developments in Non Hormonal Contraceptives Market:

Several recent developments have taken place in the field of non hormonal contraceptives market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In August 2023, Maven Clinic announced the expansion of its partnership with Amazon to support program across the world to strengthen their capabilities in reproductive endocrinologists, obstetricians, gynecologists, nutritionists, mental health providers, adoption coaches, and other care providers. 
  • In August 2023, Bill & Melinda Gates Foundation, Children’s Investment Fund Foundation, Pfizer and and Becton, Dickinson & Company (BD) expanded their partnership to enable greater access to injectable contraceptives for women in low- and lower-middle-income countries.
  • In March 2023, Kindbody raised USD 100 million funding from Perceptive Advisors with an aim to solidify its position as the largest women-owned fertility company.

Scope of the Report

The “Non Hormonal Contraceptives Market for Women’s Health  by Target Indication (Bacterial Vaginosis, Contraception, Endometriosis, Postmenopausal Osteoporosis, Uterine Fibroids, Vaginitis and Others), Type of Molecule (Biologic and Small Molecule), Purpose of Therapy (Treatment of Disease and Management of Symptoms), Mechanism of Action (Antagonist, Agonist, Inhibitor and Modulator), Route of Administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others), and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2021-2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the non hormonal contraceptives market, primarily focusing on prescription drugs. The market research report also includes an elaborate discussion on the future potential of this evolving market.

Non-Hormonal-Contraceptives-Market-Partnerships-and-Collaborations-Roots-thumb Non-Hormonal-Contraceptives-Market-Commercialization-Strategies-Roots-thumb Non-Hormonal-Contraceptives-Market-Target-Indication-Roots-thumb

Amongst other elements, the market research report features:

  • A detailed review of the overall market landscape of non-hormonal therapies, including information on their current phase of development (marketed, clinical, preclinical and discovery), type of molecule (biologic and small molecule),target indication (bacterial vaginosis, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis and others), purpose of therapy (treatment of disease and management of symptoms), target women population (adult, postmenarchal and premenopausal female, postmenopausal female), mechanism of action (antagonists, agonists, inhibitors and modulators), route of administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others) and special drug designation(s)awarded (if any).
  • A detailed review of the players engaged in the development of non-hormonal therapies, along with information on their year of establishment, company size, location of headquarters and regional landscape.
  • An elaborate discussion on the various commercialization strategies that can be adopted by drug developers engaged in non hormonal contraceptives market, across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing of the drug.
  • Detailed profiles of phase III non-hormonal therapies. Each drug profile features a brief overview of the therapy, along with information on their current development status, route of administration, primary target indication, dosage, mechanism of action, clinical trials, clinical trial results, collaborations and special drug designation(s) received(if any).
  • A detailed geographical clinical trial analysis of completed and ongoing studies of non-hormonal therapies, based on several relevant parameters, such as trial registration year, trial status, trial phase, target indication, geography, type of sponsor, prominent treatment sites and enrolled patient population.
  • An analysis of the various partnerships that have been inked by stakeholders engaged in the development of non-hormonal therapies, during the period pre 2013-2020, including research agreements, research and development agreements, contract manufacturing agreements, licensing agreements and other relevant types of deals. It further features a detailed analysis of the investments made, including award / grant, seed financing, venture capital financing, debt financing and others, in companies engaged in non hormonal birth control market.

The key objective of non hormonal contraceptives market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for non hormonal contraceptives market during the forecast period. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the forecast period 2021-2030. The market report also features the likely distribution of the current and forecasted opportunity across [A] target indication (bacterial vaginosis, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis and others), [B] type of molecule (biologic and small molecule), [C] route of administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others), [D] key geographical regions (North America, Europe and Asia-Pacific). In addition, the chapter presents indication specific value creation analysis. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are non hormonal contraceptives?

Answer: Non hormonal contraceptives are therapeutic interventions that are available, for the treatment / prevention of the clinical conditions that are unique to women. This form of therapy has been proven to be both viable and effective, and have been in use since the 1960s.

Question 2: How big is the non hormonal contraceptives market?

Answer: The non hormonal contraceptives market size is estimated to be worth $1.8 billion in 2021.

Question 3: What is the projected market growth of the non hormonal contraceptives market?

Answer: The non hormonal contraceptives market is expected to grow at compounded annual growth rate (CAGR) of 22% during the forecast period 2021 – 2030.

Question 4: How many product candidates are currently marketed / under development by players engaged in the non hormonal contraceptives market?

Answer: Over 55 product candidates are currently marketed / under development by players engaged in the non hormonal contraceptives market.

Question 5: How many clinical trials have been registered related to the non hormonal contraceptives market?

Answer: More than 220 clinical trials have been registered related to the non hormonal contraceptives market for evaluating the safety of non hormonal therapies.

Question 6: How much money has been invested by the stakeholders in non hormonal contraceptives market?

Answer: Over the last five years, more than USD 800 million has been invested by the stakeholders in non hormonal contraceptives market.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com